apixaban Clinical Research Trials

featured

Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

diabetes

cardiac monitoring

vascular disease

stroke

atrial fibrillation

314 views
24 Nov, 2020
1 location

AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

(apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

0 views
24 Jan, 2021

Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension

and TIPSS (transjugular intrahepatic portosystemic shunt) or liver transplantation for severe cases. The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH

0 views
04 Mar, 2021
1 location

Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

atrial fibrillation. They also replaced oral and parenteral anticoagulants in the treatment and prevention of deep vein thrombosis. Among the 4 available NOACs today, only apixaban had received approval

0 views
25 Jan, 2021
2 locations

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

There is a need to determine actual compliance of direct oral anticoagulants and how to improve this to reduce risk of stroke in patients with atrial fibrillation. Mobile health tools have been implemented world-wide in various patient populations as means of reducing cardiovascular risk and improving disease management. Results of …

4 views
08 Apr, 2021
1 location

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.

0 views
28 Mar, 2021
1 location

Apixaban for Extended Anticoagulation (APIDULCIS)

with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

thrombosis

venous thromboembolism

clot

deep vein thrombosis

pulmonary embolism

6 views
27 Mar, 2021
1 location

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

heparin

vitamin k antagonist

venous thromboembolism

apixaban

vitamin k

0 views
18 Apr, 2021
166 locations

API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous

8 views
05 Mar, 2021
120 locations

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.

0 views
25 Mar, 2021
4 locations

Filter By

Found 70 clinical trials